Top Story

Decline in cervical lesions driven by HPV vaccination

May 28, 2017

Age and cohort patterns seen in recent data showed that declines in high-grade cervical lesions among young women are likely driven by HPV vaccination, not changes in screening or risk behaviors, according to findings published in Clinical Infectious Diseases.

“Cervical lesions are clinically important outcomes to monitor because they are most closely related to the development of cervical cancer and because they are diagnoses that incur substantial morbidity, psychological distress and treatment cost,” Linda M. Niccolai, PhD, from the Connecticut emerging infections program at Yale School of Public Health, and colleagues wrote. “Though evidence of the impact of HPV vaccines on cervical infections and genital warts is growing, less is known about trends in precancerous high-grade cervical lesions.”

Loyola Medicine appoints vice chair in radiation oncology department

May 28, 2017
Raymond B. Wynn, MD, FACR, has been appointed vice chair of network operations in the department of radiation oncology at Loyola Medicine. Wynn — who also will…

Dana-Farber Cancer Institute appoints gastrointestinal cancer center director

May 27, 2017
Brian Wolpin , MD, MPH, has been appointed director of the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute. Wolpin is chair in pancreatic…
FDA News

FDA expands approval of Zykadia for ALK–positive metastatic NSCLC

May 26, 2017
The FDA expanded the approval of ceritinib to include the first-line treatment of patients with metastatic non–small cell lung cancer, according to the…
In the Journals Plus

Reduced-intensity, standard conditioning demonstrate comparable transplant outcomes in myelodysplastic syndrome

May 26, 2017
A reduced-intensity conditioning regimen yielded comparable RFS and OS as standard myeloablative conditioning among patients with myelodysplastic syndrome, according to…
More News Headlines »

Combination Strategies in Melanoma Management: What’s New and What’s Next

This activity is supported by an educational grant from Genentech, Inc.

Melanoma is the sixth most common cancer in the United States and the deadliest form of skin cancer. Although it is…
More »
Meeting News

VIDEO: Speaker offers updates on combinations, sequencing of immunotherapies for melanoma

April 12, 2017
More »
ASCO Annual Meeting

ASCO Annual Meeting


Immune Checkpoint Inhibitors for Advanced Melanoma: Clinical Updates and Multidisciplinary Strategies

This activity is supported by an educational grant from Bristol-Myers Squibb.

Incidence rates of melanoma in the United States continue to rise, with an estimated 87,110 new cases being diagnosed…
More »
Current Issues
View the Current Issue
HemOnc Today